Vanguard Group Inc Catalyst Biosciences, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.33 - $0.65 $68,277 - $134,485	206,900 New	206,900 $99,000
Q4 2022 Feb 10, 2023	SELL	$0.49 - $0.57 $18,260 - $21,241	-37,266 Reduced 2.71%	1,335,746 $707,000
Q2 2022 Aug 12, 2022	SELL	$0.36 - $1.78 $7,380 - $36,490	-20,500 Reduced 1.47%	1,373,012 $2.44 Million
Q4 2021 Feb 14, 2022	SELL	$0.91 - $4.16 $27,181 - $124,259	-29,870 Reduced 2.1%	1,393,512 $1.27 Million
Q3 2021 Nov 12, 2021	BUY	$3.78 - $5.18 $3,972 - $5,444	1,051 Added 0.07%	1,423,382 $5.85 Million
Q2 2021 Aug 13, 2021	BUY	$4.1 - $5.33 $5.83 Million - $7.58 Million	1,422,331 New	1,422,331 $6.16 Million

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.